Post‐ TIPS Dynamics of von Willebrand Factor for Risk Stratification After TIPS Placement
Open Access
- 8 June 2026
- journal article
- Published by Wiley in Liver International
- Vol. 46 (7) , e70736
Abstract
Background & Aims: Transjugular intrahepatic portosystemic shunt (TIPS) placement is used to treat complications of portal hypertension. This study aimed to evaluate the prognostic value of von Willebrand factor antigen (VWF) dynamics following TIPS placement. Methods: Patients with TIPS placement at the Medical University of Vienna (2018–2025) and University Medical Center Mainz (2022–2025) with available VWF at baseline (BL) were included. Patients from both cohorts with available VWF after 3 months (M3) were included in the combined longitudinal cohort (CLC). Meaningful VWF decrease (VWF‐Response) was defined as a relative VWF change (ΔVWF) of at least −5% at M3. Patients were stratified by presence of VWF‐Response and interleukin‐6 decrease (IL6‐Response) into three groups: both (R2), either/or (R1), and neither (R0). Results: Overall, 113 and 86 patients were included in the Vienna and Mainz cohorts, respectively. BL VWF was not associated with mortality in both cohorts. 118 patients constituted the CLC, which showed median BL VWF of 313.0% that decreased to 262.0% at M3 ( p = 0.007). Fifty‐three patients (44.9%) achieved VWF‐Response. Both, VWF change (ΔVWF; asHR: 2.75; 95% CI: 1.07–7.11; p = 0.037) and VWF‐Response (asHR: 0.24; 95% CI: 0.09–0.61; p = 0.003) were independently associated with survival. According to VWF and IL6 responses, patients were stratified as low‐risk (R2), versus intermediate‐risk (R1) versus high‐risk (R0) with a cumulative incidence of death at 2 years of follow‐up of R2: 10.6% versus R1: 23.1% versus R0: 46.7%, respectively. Conclusion: After TIPS placement, VWF‐Response identifies patients with a favourable prognosis and can be combined with IL6‐Response for risk stratification regarding mortality.Keywords
Funding Information
- Österreichische Gesellschaft für Gastroenterologie und Hepatologie
- Ludwig Boltzmann Gesellschaft (LBG_KFG_22_32)
- Dr. Rolf M. Schwiete Stiftung (2022‐56)
This publication has 21 references indexed in Scilit:
- Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory responseHepatology International, 2023
- Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and DeathClinical Gastroenterology and Hepatology, 2022
- Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunctionJournal of Hepatology, 2021
- Noninvasive Diagnostics for Portal Hypertension: A Comprehensive ReviewSeminars in Liver Disease, 2020
- Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severityAlimentary Pharmacology & Therapeutics, 2018
- Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosisJournal of Hepatology, 2017
- von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopeniaJournal of Hepatology, 2016
- Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPSGut, 2011
- Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertensionGut, 2011
- Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levelsJournal of Hepatology, 1999